591 related articles for article (PubMed ID: 30589644)
1. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
[TBL] [Abstract][Full Text] [Related]
2. Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Alvarado-Cruz I; Mahmoud M; Khan M; Zhao S; Oeck S; Meas R; Clairmont K; Quintana V; Zhu Y; Porciuncula A; Wyatt H; Ma S; Shyr Y; Kong Y; LoRusso PM; Laverty D; Nagel ZD; Schalper KA; Krauthammer M; Sweasy JB
Biochem Pharmacol; 2021 Feb; 184():114359. PubMed ID: 33285109
[TBL] [Abstract][Full Text] [Related]
3. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A
Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
[TBL] [Abstract][Full Text] [Related]
5. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
6. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
7. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
8. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
9. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
10. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
[TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
12. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway.
Dong Q; Yu T; Chen B; Liu M; Sun X; Cao H; Liu K; Xu H; Wang Y; Zhuang S; Jin Z; Liang H; Hui Y; Gu Y
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937640
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
15. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity.
Li GL; Ding GX; Zeng L; Ming SL; Fu PF; Wang Q; Yang GY; Wang J; Chu BB
J Virol; 2021 Jul; 95(16):e0076021. PubMed ID: 34037418
[TBL] [Abstract][Full Text] [Related]
18. DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
Wang S; Liu F; Zhu J; Chen P; Liu H; Liu Q; Han J
Med Sci Monit; 2016 Jun; 22():1999-2005. PubMed ID: 27289442
[TBL] [Abstract][Full Text] [Related]
19. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.
McLaughlin LJ; Stojanovic L; Kogan AA; Rutherford JL; Choi EY; Yen RC; Xia L; Zou Y; Lapidus RG; Baylin SB; Topper MJ; Rassool FV
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17785-17795. PubMed ID: 32651270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
